ArticleFrontiers in immunology2022
Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Development of Celiac Disease After Immunotherapy: A Case Series.Gastro hep advances · 2026Article
- Severe edema as an immune-related adverse event following nivolumab therapy: a case report.AME case reports · 2026Article
- Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.Nature reviews. Clinical oncology · 2025Review
- Immune Checkpoint Inhibitor-Associated Celiac Disease: A Retrospective Analysis and Literature Review.Diseases (Basel, Switzerland) · 2024Review
- Immune mechanisms of toxicity from checkpoint inhibitors.Trends in cancer · 2023Review
- Checkpoint Inhibitor-Induced Colitis: An Update.Biomedicines · 2023Review
- An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management.Frontiers in immunology · 2023Review
- Primate liver tissue substrate in indirect immunofluorescence diagnostics for patients with dermatitis herpetiformis and celiac disease.Frontiers in immunology · 2023Article
- Update on Immune Checkpoint Inhibitor Enterocolitis.Current gastroenterology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (irAEs) continues to rise, and rare toxicity continues to be reported. Here, we present a case of a 70-year-old male patient with widespread metastatic melanoma who developed rapid onset anasarca and transaminitis after initiation of dual anti-PD-1/CTLA-4 inhibition with nivolumab and ipilimumab. An extensive workup was performed with serologies returning positive for anti-tissue transglutaminase immunoglobulin (tTG-IgA) and endoscopy revealing duodenal mucosal atrophy with duodenal biopsies confirming celiac disease. All symptoms resolved after initiation of a gluten-free diet without the addition of immunosuppression. This case highlights the importance of considering celiac disease in patients with suspected protein-losing enteropathy on ICI, the fulminant nature this uncommon irAE can present with, and underscores the broad differential clinicians must maintain when managing presumed irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.